0000899243-23-004747.txt : 20230213 0000899243-23-004747.hdr.sgml : 20230213 20230213161543 ACCESSION NUMBER: 0000899243-23-004747 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230209 FILED AS OF DATE: 20230213 DATE AS OF CHANGE: 20230213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PAUL STEVEN M CENTRAL INDEX KEY: 0001237564 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38958 FILM NUMBER: 23618653 MAIL ADDRESS: STREET 1: C/O ELI LITTY & CO STREET 2: LIIY CORPORATE CENTER DC 1093 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Karuna Therapeutics, Inc. CENTRAL INDEX KEY: 0001771917 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 270605902 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 99 HIGH STREET STREET 2: 26TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 857-449-2244 MAIL ADDRESS: STREET 1: 99 HIGH STREET STREET 2: 26TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-09 0 0001771917 Karuna Therapeutics, Inc. KRTX 0001237564 PAUL STEVEN M C/O KARUNA THERAPEUTICS, INC. 99 HIGH STREET, FLOOR 26 BOSTON MA 02110 1 1 0 0 CSO and President of R&D Common Stock 2022-05-27 5 G 0 E 106485 0.00 D 0 I Spouse (Jann E. Paul GRAT I) Common Stock 2022-05-27 5 G 0 E 106485 0.00 A 106485 I Spouse (Jann E. Paul Revocable Trust) Common Stock 2022-05-31 5 G 0 E 106485 0.00 D 0 I Spouse (Jann E. Paul Revocable Trust) Common Stock 2022-05-31 5 G 0 E 106485 0.00 A 106485 I Spouse (Jann E. Paul GRAT III) Common Stock 2023-02-09 4 A 0 11400 0.00 A 11400 D Common Stock 2364 I The Steven M. Paul Revocable Trust Option (Right to Buy) 187.26 2023-02-09 4 A 0 22800 0.00 A 2023-02-08 Common Stock 22800 22800 D Comprised of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest annually in four 25% installments commencing on February 9, 2024, subject to continued service through such dates. 25% of this option shall vest on February 9, 2024, and the remaining 75% shall vest in twelve equal three-month installments over the following three years, subject to continued service through such dates. /s/ Troy Ignelzi, Attorney-in-fact 2023-02-13